Biohaven Rallies On Preliminary Nurtec Revenue Numbers: What Investors Need To Know
Biohaven Pharmaceutical Ltd. (NYSE: BHVN) released preliminary second-quarter revenue data for its drug Nurtec ODT on Wednesday.
What Happened: Nurtec achieved preliminary net product revenue of approximately $93 million in the second quarter, according to the company.
